By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danish drug discovery firm Nuevolution today said it will employ its screening technology as part of a consortium to identify and develop small molecule drugs against epigenetic disorders.

Nuevolution, based in Copenhagen, Denmark, joins the consortium that also includes EpiTherapeutics, ExpreS2ion Biotechnologies, and the research group of Kristian Helin at the Biotech Research & Innovation Centre at the University of Copenhagen.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.